Merck & Co.â€™s Q4 2012 earnings call indicates a mixed outlook for the stock in the short term. The company maintained sales levels despite significant patent expirations like Singulair, showing resilience in managing their core growth strategy. However, the EPS guidance for 2013 reflects challenges with continued expectation pressures from expirations and a shift in product mix towards lower-margin products. This, combined with mentions of future investment in emerging markets, R&D, and upcoming product launches, might temper investor confidence leading potentially leading to short-term stock price volatility.

[-1]